AbbVie's Q1 earnings surpassed estimates, but stock dropped 1.4% on April 29th.

AbbVie stock dropped 1.4% on April 29th with trading volume down 69% from average. Analysts' price objectives were lowered, while BMO Capital Markets declined from $195 to $180 with an "outperform" rating, and Guggenheim raised to $190 with a "buy" rating. AbbVie's Q1 reported $2.31 EPS, surpassing the consensus estimate of $2.26. Revenue hit $12.31bn, surpassing the consensus estimate of $11.93bn.